UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Role of bisphenol A as environmental factor in the promotion of non‐alcoholic fatty liver disease: in vitro and clinical study

Alimentary pharmacology & therapeutics, 2018-03, Vol.47 (6), p.826-837

2018

Volltextzugriff (PDF)

The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: role of endothelial dysfunction

European review for medical and pharmacological sciences, 2016-11, Vol.20 (22), p.4731

2016

Volltextzugriff (PDF)

Urinary volatile Organic compounds in non-alcoholic fatty liver disease (NAFLD), type two diabetes mellitus (T2DM) and NAFLD-T2DM coexistence

Metabolomics, 2022-11, Vol.18 (12), p.98-98, Article 98

2022

Volltextzugriff (PDF)

May chronic cough in chronic obstructive pulmonary disease be a contraindication of Percutaneous Endoscopic Gastrostomy placement: a case report

BMC gastroenterology, 2021-01, Vol.21 (1), p.31-31, Article 31

2021

Volltextzugriff (PDF)

A pilot study on the ability of clinoptilolite to absorb ethanol in vivo in healthy drinkers: effect of gender

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2015-06, Vol.66 (3), p.441

2015

Volltextzugriff (PDF)

Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort

Journal of hepatology, 2017, Vol.66 (1), p.S535-S535

2017

Volltextzugriff (PDF)

P.08.8: Silybin in Combination with Regorafenib as a Novel Potential Strategy for the Treatment of Metastatic Colorectal Cancer Patients

Digestive and liver disease, 2017-03, Vol.49, p.e181-e182

2017

Volltextzugriff (PDF)

P.10.2 EFFECTS OF SILYBIN ADMINISTRATION ON THE REDOX STATE AND OXIDATIVE STRESS RESPONSE OF HUMAN ENDOTHELIAL CELLS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS

Digestive and liver disease, 2016-02, Vol.48, p.e178-e178

2016

Volltextzugriff (PDF)

P.10.1 REACTIVATION OF HEPATITIS B VIRUS IN CANCER PATIENTS TREATED WITH CHEMOTHERAPY FOR SOLID TUMORS. IS THE PROPHYLAXIS REALLY REQUIRED?

Digestive and liver disease, 2016-02, Vol.48, p.e177-e177

2016

Volltextzugriff (PDF)

P.09.8: Role of Bisphenol a as Environmental Factor in the Promotion of Non-Alcoholic Fatty Liver Disease: In VITRO and in VIVO Protective Effects of Silybin

Digestive and liver disease, 2017-03, Vol.49, p.e190-e190

2017

Volltextzugriff (PDF)

Impact of SVR and Type 2 Diabetes Mellitus on liver stiffness and liver functionality in HCV infected patients with severe liver disease treated with DAA: A real life study

Digestive and liver disease, 2016-10, Vol.48, p.e234-e234

2016

Volltextzugriff (PDF)

P.01.4 ENDOCAN AS SERUM MARKER OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND/OR TYPE 2 DIABETES

Digestive and liver disease, 2016-02, Vol.48, p.e131-e131

2016

Volltextzugriff (PDF)

Crohn’s disease and skin

United European Gastroenterology Journal, 2016-04, Vol.4 (2), p.165-171

2016

Volltextzugriff (PDF)

P.14.5 THE ROLE OF HELICOBACTER PYLORI INFECTION AND SMALL INTESTINAL BACTERIAL OVERGROWTH IN ROSACEA

Digestive and liver disease, 2014-03, Vol.46, p.S110-S110

2014

Volltextzugriff (PDF)

P.17.17 SERUM CONCENTRATION OF 49 PROTEINS IN PATIENTS WITH CHRONIC GASTRITIS BY MULTIPLEX BIOMETRIC IMMUNOASSAY

Digestive and liver disease, 2014-03, Vol.46, p.S126-S126

2014

Volltextzugriff (PDF)

P.06.24 GENDER DIFFERENCE IN DERMATOLOGICAL ADVERSE EFFECTS DURING ANTIBODIES ANTI-TNF ALFA THERAPY IN CHRONIC INFLAMMATORY BOWEL DISEASE

Digestive and liver disease, 2014-03, Vol.46, p.S78-S78

2014

Volltextzugriff (PDF)

P.17.9 TELAPREVIR- OR BOCEPREVIR-BASED TRIPLE-THERAPY IN PATIENTS WITH HCV INFECTION GENOTYPE 1: ON-TREATMENT EFFICACY AND DATA ON SAFETY

Digestive and liver disease, 2014-03, Vol.46, p.S123-S123

2014

Volltextzugriff (PDF)

P.18.6 FOOD INTAKE, GASTROINTESTINAL HORMONES AND INTESTINAL PERMEABILITY IN PATIENTS WITH HCV-RELATED CHRONIC LIVER DISEASE

Digestive and liver disease, 2013-03, Vol.45, p.S211-S212

2013

Volltextzugriff (PDF)

OC.05.8: SYSTEMIC OXIDATIVE STRESS-UNBALANCE IN PBC PATIENTS CORRELATES WITH LIVER DISEASE PROGRESSION. A PRELIMINARY EVALUATION

Digestive and liver disease, 2024-04, Vol.56, p.S154-S155

2024

Volltextzugriff (PDF)

T.07.1: PREVALENCE OF DYSGEUSIA IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE (ACLD), RELATIONSHIP WITH THE LIVER-DISEASE PROGRESSION STATUS, AND IMPACT ON MALNUTRITION-SARCOPENIA-FRAILTY (THE PREDYCI STUDY)

Digestive and liver disease, 2024-04, Vol.56, p.S253-S254

2024

Volltextzugriff (PDF)

T.04.8: IBD PATIENTS SHOW WORRYING LEVELS OF SELF-REPORTED PHYSICAL INACTIVITY AS MEASURED BY THE INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE INDEPENDENTLY OF DISEASE ACTIVITY AND IBD PHENOTYPE: RESULTS FROM THE EXTENDED “BE-FIT-IBD” CROSS-SECTIONAL STUDY

Digestive and liver disease, 2024-04, Vol.56, p.S240-S241

2024

Volltextzugriff (PDF)

OC.03.3: CAN CHAT GENERATIVE PRE-TRAINED TRANSFORMER (CHATGPT) BE AN AI-PROVIDED FRIEND OF THE IBD PATIENTS FOR FREQUENTLY ASKED QUESTIONS RELATED TO THEIR DISEASE MANAGEMENT? AN EVIDENCE- AND GUIDELINESCONTROLLED TEXTUAL ANALYSIS OF AI-PROVIDED OUTPUTS

Digestive and liver disease, 2024-04, Vol.56, p.S134-S135

2024

Volltextzugriff (PDF)

T.03.5 EFFECT OF ENVIRONMENTAL BISPHENOL A EXPOSURE ON TRAINED IMMUNITY-RELATED PATHWAYS IN NON-ALCOHOLIC FATTY LIVER DISEASE: A PRELIMINARY OBSERVATION

Digestive and liver disease, 2023-03, Vol.55, p.S146-S147

2023

Volltextzugriff (PDF)

Spleen area affects the predictive performance for decompensation of the platelet count-based non-invasive tools in MASLD-related cirrhosis: a preliminary observation

Digestive and liver disease, 2024-09, Vol.56, p.S323-S323

2024

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(59)

Publikationsform

Artikel
(64)

Sprache

Englisch
(64)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Role of bisphenol A as environmental factor in the promotion of non‐alcoholic fatty liver disease: in vitro and clinical study

The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: role of endothelial dysfunction

Urinary volatile Organic compounds in non-alcoholic fatty liver disease (NAFLD), type two diabetes mellitus (T2DM) and NAFLD-T2DM coexistence

May chronic cough in chronic obstructive pulmonary disease be a contraindication of Percutaneous Endoscopic Gastrostomy placement: a case report

A pilot study on the ability of clinoptilolite to absorb ethanol in vivo in healthy drinkers: effect of gender

Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort

P.08.8: Silybin in Combination with Regorafenib as a Novel Potential Strategy for the Treatment of Metastatic Colorectal Cancer Patients

P.10.2 EFFECTS OF SILYBIN ADMINISTRATION ON THE REDOX STATE AND OXIDATIVE STRESS RESPONSE OF HUMAN ENDOTHELIAL CELLS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS

P.10.1 REACTIVATION OF HEPATITIS B VIRUS IN CANCER PATIENTS TREATED WITH CHEMOTHERAPY FOR SOLID TUMORS. IS THE PROPHYLAXIS REALLY REQUIRED?

P.09.8: Role of Bisphenol a as Environmental Factor in the Promotion of Non-Alcoholic Fatty Liver Disease: In VITRO and in VIVO Protective Effects of Silybin

Impact of SVR and Type 2 Diabetes Mellitus on liver stiffness and liver functionality in HCV infected patients with severe liver disease treated with DAA: A real life study

P.01.4 ENDOCAN AS SERUM MARKER OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND/OR TYPE 2 DIABETES

Crohn’s disease and skin

P.14.5 THE ROLE OF HELICOBACTER PYLORI INFECTION AND SMALL INTESTINAL BACTERIAL OVERGROWTH IN ROSACEA

P.17.17 SERUM CONCENTRATION OF 49 PROTEINS IN PATIENTS WITH CHRONIC GASTRITIS BY MULTIPLEX BIOMETRIC IMMUNOASSAY

P.06.24 GENDER DIFFERENCE IN DERMATOLOGICAL ADVERSE EFFECTS DURING ANTIBODIES ANTI-TNF ALFA THERAPY IN CHRONIC INFLAMMATORY BOWEL DISEASE

P.17.9 TELAPREVIR- OR BOCEPREVIR-BASED TRIPLE-THERAPY IN PATIENTS WITH HCV INFECTION GENOTYPE 1: ON-TREATMENT EFFICACY AND DATA ON SAFETY

P.18.6 FOOD INTAKE, GASTROINTESTINAL HORMONES AND INTESTINAL PERMEABILITY IN PATIENTS WITH HCV-RELATED CHRONIC LIVER DISEASE

Steatosis in patients with HCV chronic liver disease: Baseline results from patients enrolled in the PITER cohort study

OC.05.8: SYSTEMIC OXIDATIVE STRESS-UNBALANCE IN PBC PATIENTS CORRELATES WITH LIVER DISEASE PROGRESSION. A PRELIMINARY EVALUATION

T.07.1: PREVALENCE OF DYSGEUSIA IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE (ACLD), RELATIONSHIP WITH THE LIVER-DISEASE PROGRESSION STATUS, AND IMPACT ON MALNUTRITION-SARCOPENIA-FRAILTY (THE PREDYCI STUDY)

T.04.8: IBD PATIENTS SHOW WORRYING LEVELS OF SELF-REPORTED PHYSICAL INACTIVITY AS MEASURED BY THE INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE INDEPENDENTLY OF DISEASE ACTIVITY AND IBD PHENOTYPE: RESULTS FROM THE EXTENDED “BE-FIT-IBD” CROSS-SECTIONAL STUDY

OC.03.3: CAN CHAT GENERATIVE PRE-TRAINED TRANSFORMER (CHATGPT) BE AN AI-PROVIDED FRIEND OF THE IBD PATIENTS FOR FREQUENTLY ASKED QUESTIONS RELATED TO THEIR DISEASE MANAGEMENT? AN EVIDENCE- AND GUIDELINESCONTROLLED TEXTUAL ANALYSIS OF AI-PROVIDED OUTPUTS

T.03.5 EFFECT OF ENVIRONMENTAL BISPHENOL A EXPOSURE ON TRAINED IMMUNITY-RELATED PATHWAYS IN NON-ALCOHOLIC FATTY LIVER DISEASE: A PRELIMINARY OBSERVATION

Spleen area affects the predictive performance for decompensation of the platelet count-based non-invasive tools in MASLD-related cirrhosis: a preliminary observation

Suchergebnisse filtern